Evolution of Multitarget Strategies for Alzheimer’s Disease: From Cholinergic Inhibition to Network-Oriented Therapeutic Design (2006–2025)
Pharmaceuticals · 30.06.2026 · 19 (7) · 1024
DOI: 10.3390/ph19071024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 30.06.2026. Verfasst von Jaime Mella und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Química, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Central University of Chile, Universidad Central de Chile.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer’s disease (AD) is a complex neurodegenerative disorder and a major global health challenge. The traditional “one drug–one target” paradigm has shown limitations in addressing its multifactorial nature. Multitarget-directed ligands (MTDLs), designed to modulate multiple pathological pathways, have emerged as a promising therapeutic strategy.
Objectives
To examine the structural, thematic, and temporal evolution of multitarget strategies for AD treatment between 2006 and 2025.
Methods
A total of 1184 Web of Science-indexed articles were analyzed. Publication growth, h-index, author productivity, institutional and national contributions, and keyword co-occurrence networks were evaluated using VOSviewer. Bibliometric laws (Price, Bradford, Zipf, and Lotka) were applied to characterize productivity patterns and thematic organization.
Results
Multitarget research shows exponential growth, suggesting a consolidation of the MTDL paradigm. China, India, the United States, Italy, and Spain were the most productive countries. Early studies focused on cholinesterase inhibition, particularly acetylcholinesterase-based hybrids. The field expanded to include β-amyloid aggregation, oxidative stress, metal chelation, and blood–brain barrier permeability. Recent trends emphasize integration of computational approaches, including molecular docking, molecular dynamics, virtual screening, and network pharmacology, alongside targets such as BACE1 and GSK-3β.
Conclusions
Multitarget strategies have evolved toward a systems-oriented framework. Despite advances, challenges remain in reducing cholinesterase dependency and improving translational validation. This study provides a framework to interpret therapeutic evolution and guide future network-based drug design.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Química, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.
- Centro de Investigación, Desarrollo e Innovación de Productos Bioactivos (CInBIO), Universidad de Valparaíso, Valparaíso 2360102, Chile.
- Laboratorio de Bienestar y Comportamiento Organizacional, Facultad de Medicina y Ciencias de la Salud, Universidad Central de Chile, Santiago 8330507, Chile.
- Centro de Investigación en Medicina de Altura, Universidad Arturo Prat, Santiago 8340232, Chile.
- Departamento de Química, Universidad Técnica Federico Santa María, Av. España 1680, Valparaíso 2340000, Chile.
- Laboratorio de Fisiología, Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad de Tarapacá, Arica 1000000, Chile.
ORCID-Profile: Jaime Mella, Alejandro Vega-Muñoz, Mauricio Soto, Daniel Moraga, Javier Campanini-Salinas, Eduardo Sandoval-Obando, Guido Salazar-Sepúlveda, Natalia Salas-Guzmán, Remik Carabantes-Silva, Marco Mellado
Förderung
- Central University of Chile
- Universidad Central de Chile
Zitieren
APA
Mella, J., Vega-Muñoz, A., Soto, M., Moraga, D., Campanini-Salinas, J., Sandoval-Obando, E., Contreras-Barraza, N., Salazar-Sepúlveda, G., Salas-Guzmán, N., Carabantes-Silva, R., & Mellado, M. (2026). Evolution of Multitarget Strategies for Alzheimer’s Disease: From Cholinergic Inhibition to Network-Oriented Therapeutic Design (2006–2025). Pharmaceuticals, 19(7), 1024. https://doi.org/10.3390/ph19071024
Vancouver
Mella J, Vega-Muñoz A, Soto M, Moraga D, Campanini-Salinas J, Sandoval-Obando E, et al. Evolution of Multitarget Strategies for Alzheimer’s Disease: From Cholinergic Inhibition to Network-Oriented Therapeutic Design (2006–2025). Pharmaceuticals. 2026;19(7):1024. doi:10.3390/ph19071024
BibTeX
@article{Mella2026,
author = {Mella, Jaime and Vega-Muñoz, Alejandro and Soto, Mauricio and Moraga, Daniel and Campanini-Salinas, Javier and Sandoval-Obando, Eduardo and Contreras-Barraza, Nicolás and Salazar-Sepúlveda, Guido and Salas-Guzmán, Natalia and Carabantes-Silva, Remik and Mellado, Marco},
title = {Evolution of Multitarget Strategies for Alzheimer’s Disease: From Cholinergic Inhibition to Network-Oriented Therapeutic Design (2006–2025)},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1024},
doi = {10.3390/ph19071024}
}
EUVIMED